Loading...
XSHE
000590
Market cap462mUSD
Jul 15, Last price  
13.86CNY
1D
0.00%
1Q
59.31%
Jan 2017
-29.47%
Name

Tus Pharmaceutical Group Co Ltd

Chart & Performance

D1W1MN
P/E
P/S
9.67
EPS
Div Yield, %
Shrs. gr., 5y
Rev. gr., 5y
1.73%
Revenues
343m
-15.18%
271,110,822286,824,832207,905,036236,573,558274,089,961311,624,913343,508,517363,420,444256,000,679203,122,000294,719,555317,410,504343,539,198185,811,015315,034,457275,090,121300,774,612350,528,110404,647,908343,208,128
Net income
0k
-100.00%
4,290,0122,894,26120,517,35020,374,461047,153,71372,134,381137,606,3350022,372,28255,175,21519,173,756042,442,30822,722,39735,438,60318,109,85425,246,7780
CFO
17m
P
55,959,294068,039,94934,885,63234,144,67784,978,22630,866,20619,746,0604,122,1590000654,23729,208,43651,480,57925,196,29654,473,687-28,394,71717,387,972
Dividend
Jun 21, 20130.2 CNY/sh

Profile

Tus-Pharmaceutical Group Co., Ltd. manufactures and sells traditional Chinese medicine and western medicine products. The company was formerly known as Tus-Guhan Group Corp.,Ltd. Tus-Pharmaceutical Group Co., Ltd. was founded in 1956 and is based in Hengyang, China.
IPO date
Jan 19, 1996
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
343,208
-15.18%
404,648
15.44%
350,528
16.54%
Cost of revenue
249,792
271,290
261,211
Unusual Expense (Income)
NOPBT
93,416
133,358
89,317
NOPBT Margin
27.22%
32.96%
25.48%
Operating Taxes
5,092
4,789
3,704
Tax Rate
5.45%
3.59%
4.15%
NOPAT
88,325
128,569
85,614
Net income
25,247
39.41%
18,110
-48.90%
Dividends
(4,195)
(338)
Dividend yield
0.20%
0.02%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
755
10,000
38,616
Long-term debt
85,204
86,141
100,352
Deferred revenue
43,990
44,366
Other long-term liabilities
43,069
42,720
46,095
Net debt
(91,333)
(114,529)
(121,562)
Cash flow
Cash from operating activities
17,388
(28,395)
54,474
CAPEX
(22,042)
Cash from investing activities
4,153
Cash from financing activities
(31,513)
111,520
FCF
81,380
46,970
45,052
Balance
Cash
177,292
189,770
260,530
Long term investments
2
20,900
Excess cash
160,131
190,437
243,004
Stockholders' equity
242,458
396,734
386,092
Invested Capital
612,629
715,999
666,934
ROIC
13.30%
18.59%
15.13%
ROCE
12.01%
14.62%
9.74%
EV
Common stock shares outstanding
239,471
239,471
239,471
Price
7.11
-20.65%
8.96
0.22%
8.94
-9.51%
Market cap
1,702,641
-20.65%
2,145,663
0.22%
2,140,873
-9.51%
EV
1,614,295
2,035,619
2,023,337
EBITDA
122,630
161,399
113,677
EV/EBITDA
13.16
12.61
17.80
Interest
3,662
4,462
1,154
Interest/NOPBT
3.92%
3.35%
1.29%